Table 3.
Univariate and multivariate analysis of clinical variables and gene signatures for overall (A) and early (B) recurrence.
| A | OVERALL RECURRENCE
|
|||||||
|---|---|---|---|---|---|---|---|---|
| UNIVARIATE ANALYSIS | MULTIVARIATE ANALYSIS | |||||||
| Variables | n | P-value | HR | 95% CI | n | P-value | HR | 95% CI |
| Origin (Japan) | 244 | 0.766 | 1.05 | 0.75-1.49 | ||||
| Gender (Male) | 244 | 0.520 | 1.13 | 0.78-1.62 | ||||
| Age (>60) | 241 | 0.556 | 0.91 | 0.66-1.25 | ||||
| Etiology (HCV) | 242 | 0.240 | 1.22 | 0.88-1.70 | ||||
| Size (>2 cm) | 244 | 0.471 | 1.14 | 0.80-1.63 | ||||
| Albumin (<3.5 g/L) | 237 | 0.090 | 1.49 | 0.94-2.37 | ||||
| Bilirubin (>1 mg/dL) | 240 | 0.341 | 0.85 | 0.61-1.19 | ||||
| Platelet count (<100,000/mm3) | 240 | 0.423 | 1.17 | 0.80-1.72 | ||||
| AFP (>100 mg/dL) | 234 | 0.330 | 0.830 | 0.57-1.20 | ||||
| Vascular invasion | 239 | 0.321 | 1.18 | 0.85-1.65 | ||||
| Satellites | 241 | 0.016 | 1.70 | 1.10-2.62 | 198 | 0.041 | 1.66 | 1.02-2.71 |
| Degree of differentiation (moderately or poor) | 241 | 0.548 | 1.12 | 0.77-1.62 | ||||
| BCLC stage (A) | 244 | 0.509 | 1.15 | 0.76-1.76 | ||||
| Signature of metastatic HCC | 244 | 0.383 | 0.64 | 0.24-1.74 | ||||
| G3 signature | 244 | 0.011 | 1.55 | 1.11-2.16 | 198 | 0.003 | 1.75 | 1.20-2.53 |
| Proliferation class | 244 | 0.665 | 1.07 | 0.78-1.49 | ||||
| CK19 signature | 244 | 0.971 | 1.01 | 0.72-1.41 | ||||
| Ck19 rat signature | 244 | 0.828 | 1.04 | 0.74-1.47 | ||||
| Vascular invasion signature | 244 | 0.921 | 0.98 | 0.66-1.45 | ||||
| Late TGFB | 244 | 0.517 | 0.88 | 0.60-1.29 | ||||
| Cluster A | 244 | 0.496 | 1.12 | 0.80-1.58 | ||||
| MET signature | 244 | 0.891 | 1.03 | 0.66-1.61 | ||||
| HCC recurrence signature | 244 | 0.490 | 0.88 | 0.62-1.26 | ||||
| EPCAM signature | 244 | 0.506 | 0.83 | 0.49-1.42 | ||||
| Hepatoblastoma C2 | 244 | 0.661 | 0.87 | 0.47-1.61 | ||||
| Class S1 | 244 | 0.883 | 1.03 | 0.72-1.47 | ||||
| Class S2 | 244 | 0.791 | 1.06 | 0.69-1.63 | ||||
| Colangiocarcinoma signature | 244 | 0.485 | 0.88 | 0.64-1.23 | ||||
| Poor survival signature* | 201 | 0.007 | 1.67 | 1.15-2.44 | 198 | 0.004 | 1.74 | 1.19-2.55 |
|
| ||||||||
| B |
EARLY RECURRENCE
|
|||||||
| UNIVARIATE ANALYSIS | MULTIVARIATE ANALYSIS | |||||||
|
| ||||||||
| Variables | n | P-value | HR | 95% CI | n | P-value | HR | 95% CI |
|
| ||||||||
| Origin (Japan) | 244 | 0.325 | 1.26 | 0.80-1.98 | ||||
| Gender (Male) | 244 | 0.522 | 1.17 | 0.72-1.92 | ||||
| Age (>60) | 241 | 0.412 | 0.84 | 0.54-1.28 | ||||
| Etiology (HCV) | 242 | 0.809 | 0.95 | 0.62-1.46 | ||||
| Size (>2 cm) | 244 | 0.037 | 1.78 | 1.03-3.06 | 193 | 0.109 | 1.62 | 0.89-2.92 |
| Albumin (<3.5 g/L) | 237 | 0.085 | 1.65 | 0.93-2.94 | ||||
| Bilirubin (>1 mg/dL) | 240 | 0.595 | 1.13 | 0.73-1.75 | ||||
| Platelet count (<100,000/mm3) | 240 | 0.939 | 1.02 | 0.61-1.72 | ||||
| AFP (>100 mg/dL) | 234 | 0.607 | 1.13 | 0.70-1.81 | ||||
| Vascular invasion | 239 | 0.039 | 1.57 | 1.02-2.40 | 193 | 0.950 | 1.01 | 0.59-1.73 |
| Satellites | 241 | 0.012 | 1.91 | 1.15-3.18 | 193 | 0.041 | 1.80 | 1.02-3.18 |
| Degree of differentiation (moderately or poor) | 241 | 0.059 | 1.71 | 0.98-2.99 | ||||
| BCLC stage (A) | 244 | 0.24 | 1.46 | 0.78-2.27 | ||||
| Signature of metastatic HCC | 244 | 0.572 | 0.67 | 0.16-2.71 | ||||
| G3 signature | 244 | 0.001 | 1.99 | 1.30-3.05 | 193 | 0.033 | 1.71 | 1.04-2.81 |
| Proliferation class | 244 | 0.073 | 1.47 | 0.96-2.25 | ||||
| CK19 signature | 244 | 0.135 | 1.39 | 0.90-2.14 | ||||
| CK19 rat signature | 244 | 0.242 | 1.30 | 0.84-2.04 | ||||
| Vascular invasion signature | 244 | 0.38 | 1.25 | 0.76-2.04 | ||||
| Late TGFB | 244 | 0.193 | 1.37 | 0.85-2.19 | ||||
| Cluster A | 244 | 0.142 | 1.39 | 0.90-2.14 | ||||
| MET signature | 244 | 0.865 | 0.95 | 0.52-1.74 | ||||
| HCC recurrence signature | 244 | 0.534 | 0.86 | 0.52-1.40 | ||||
| EPCAM signature | 244 | 0.247 | 0.61 | 0.27-1.41 | ||||
| Hepatoblastoma C2 | 244 | 0.889 | 0.94 | 0.41-2.16 | ||||
| Class S1 | 244 | 0.84 | 1.05 | 0.65-1.69 | ||||
| Class S2 | 244 | 0.347 | 1.30 | 0.75-2.23 | ||||
| Colangiocarcinoma signature | 244 | 0.441 | 1.18 | 0.77-1.81 | ||||
| Poor survival signature* | 201 | 0.007 | 1.88 | 1.18-2.98 | 193 | 0.006 | 1.92 | 1.20-3.06 |
*
Signature generated in adjacent non-tumoral cirrhotic tissue